Featured tickers: $ABBV $ACOR $AGIO $BMY $CLDX $CRDC $CYNAF $CYTX $ENTA $EPZM $ERTM $FOLD $GILD $ICPT $MDT $MDVN $MRK $NBS $NWBO $PFE $RCPT $RMTI $RTRX $TKMR $UNH $VRTX $XLRN $ZGNX
Note you can use the search box at the upper right to find all BiotechDueDiligence content related to a particular stock of interest.
Thought it was Monday morning given the glut of cancer data in my inbox!
— Sally Church (@MaverickNY) November 16, 2014 $MRK barely IMPROVE-IT
— zach (@zbiotech) November 17, 2014 At some point the "learning curve" justification for poor results just means you suck
— daviesbj (@daviesbj) November 15, 2014 @JacobEPVantage maturity and biotech are not usually two words you se in the same sentence
— Sally Church (@MaverickNY) November 17, 2014 How awesome is it that one of the best trading opportunities of the year happened in the last minutes of Friday. Only the dedicated win.
— Brad Loncar (@bradloncar) November 17, 2014 @ldtimmerman Academia meets capitalism. For once all those painfully (& usually uselessly) negotiated license clauses might actually pay off
— Brian Gallagher, Jr. (@bmgallagherjr) November 18, 2014 Juno might be biotech's version of $BABA. Everybody is going to want a piece of that one.
— Brad Loncar (@bradloncar) November 17, 2014 RT @MaverickNY: $BMY data is huge - Nivo will be front-line & pembro in post ipillimumab setting. Which would u rather have?
— Joe (@GantosJ) November 17, 2014 @bradloncar does she tweet? #bestdayofherlife ?
— Red Acre Investments (@redacre) November 17, 2014 Trailing stop loss of .20 took me out of rest of $CLDX at 17.04 from 13.99
— DeadCatBill (@getbillasap) November 17, 2014 @AndyBiotech I am beginning to think they are cursed, sell whatever they touch :-)
— JQ (@jq1234t) November 17, 2014 .@scientre yes, impt point. Its not just diversity of gender, color, and age. Its diversity of thought. More powerful
— Luke Timmerman (@ldtimmerman) November 17, 2014 CEO of UnitedHealthcare made >$50M in total comp over the last 5 yrs, but it took me 45 minutes on hold to speak to a script-reading agent.
— David Maizenberg (@biologypartners) November 17, 2014 So $crdc basically said their stapler sucks. Pulling due to doc feedback from limited launch.
— NathanAaron (@NathanAhron) November 18, 2014 Subway to 42nd St: $2. Coffee at the Hyatt $4. An in depth talk about biopharma and drug development with @scientre PRICELESS.Thanks Laura!
— David Sable (@dbsable) November 18, 2014 $ICPT long 5 DEC $175 calls at $8.50
— Rick (@Skipjackrick) November 18, 2014 "Angel investing [in biomedical research] is like raising kids. Needs time, focus, nurture, but it can be very rewarding."@edyson #p4c2014
— EmilyKramerGolinkoff (@emilykg1) November 18, 2014 Good luck to longs and shorts! I am long, I'll be upset if it poops, but I had conviction and that helps me not to get too upset. $CYNAF
— Alfredo Fontanini (@AF_biotech) November 19, 2014 $FOLD nice buying opportunity this morning.
— Brad Loncar (@bradloncar) November 18, 2014 $fold raise 90M, was well overrx. Price at 6.50
— NathanAaron (@NathanAhron) November 19, 2014 How to interpret Bio-Tweets, part 6: "Stock ____ is overvalued!" Translation: I was stupid and didn't buy it $60 cheaper.
— Adam Feuerstein (@adamfeuerstein) November 19, 2014 .@JohnCFierce If it's for anything from current pipeline, maybe ammo buildup for future war in NASH?
— Andy Biotech (@AndyBiotech) November 19, 2014 Just received saddest email ever: reason for unsubscribing - Deceased. Let's not forget there's real people involved in cancer trials
— Sally Church (@MaverickNY) November 19, 2014 Using Civitas as a comp, $CYNAF is worth $3.65 per share. Drug is better, timing is nearly identical. $ACOR bought the wrong drug.
— Jason Napodano, CFA (@JNapodano) November 19, 2014 $AGIO up 17% today.
— John Carroll (@JohnCFierce) November 19, 2014 Sold all 50 $NBS put contracts at 0.65 for #zzporte profit of $1250 for a symbolic victory over the forces of evil @portefeuillefun
— Tony Friedman (@zzlangerhans) November 19, 2014 @adamfeuerstein @JohnCFierce sad. That $25M could have been invested in other ventures, or given a better use
— Juan P. Serrate, DVM (@JPZaragoza1) November 19, 2014 I still cannot believe it. 3.3 BILLION with a B dollars for #cysticfibrosis research. Amazing. Unbelievable. Transformational. #Hopeful
— Erin Moore (@ekeeleymoore) November 19, 2014 The real sleeper news on $GILD is that its priority voucher could be worth much more in a few months. Here's why: http://t.co/NxdvWrcFZZ
— Alexander Gaffney (@AlecGaffney) November 19, 2014 $RMTI just broke under the offering price $9
— Amit Gupta (@amitp_gupta) November 20, 2014 Here's the winning #bjtcawards Radio Documentary on dementia that @3NT did earlier this year: http://t.co/OFmepnXUhQ cool stuff!
— Sally Church (@MaverickNY) November 20, 2014 @dbsable @Dereklowe @Columbia love how you use twitter to book speakers....so cool
— NathanAaron (@NathanAhron) November 20, 2014 @lipscrl would be nice to see market just trend....volatility chopped me up. I'm net nowhere last 2 months.
— Festo (@Festo50) November 20, 2014 Or someone trying to sell before scrip data tmrw - either or... RT @zbiotech: rumor of activist interest in $GILD icahn
— Ian Estepan (@ianestepan) November 20, 2014 FDA approves Purdue Pharma’s Hysingla ER — extended release hydrocodone with abuse deterrence. $ZGNX
— Adam Feuerstein (@adamfeuerstein) November 20, 2014 Excited to be representing @xnBioPartners and @PropThinker at $TKMR analyst day tomorrow in NYC
— Zack (@BioTerp) November 20, 2014 Added to $gild $enta. Started $xoma $myl. Sold $kite $cnat. Stared at 89620x100 (I mean $sctpf) wondering what the hell?
— Joe (@Drchik23) November 20, 2014 @VikramKhanna_ If $AGIO presented the $EPZM data it would have been up 10%+
— David Sobek (@dsobek) November 20, 2014 @JacobEPVantage Yes, highly unlikely. I am pretty sure that assuming Royalty Pharma knows what it's doing $VRTX is undervalued.
— V.S. Schulz (@portefeuillefun) November 20, 2014 $RCPT is already 18% above its offering price. Textbook case of a good raise.
— Brad Loncar (@bradloncar) November 20, 2014 @ColfaxCapital @AlpineBV_Miller $xlrn has the same problem. Odd how some stocks are like that.
— David Sobek (@dsobek) November 21, 2014 Off to dd for other neuros: do you have ideas you want to share?
— Alfredo Fontanini (@AF_biotech) November 21, 2014 $ETRM Expect $MDT buyout with FDA approval soon. Both based in Minneapolis - CEO Mark Knudson previously sold Restore Med to $MDT
— S Manian (@DrSManian) November 21, 2014 $ABBV EU MEDICINES AGENCY RECOMMENDS ABBVIE HEPATITIS C DRUG DASABUVIR
— Captain Sequence (@CaptainFuture__) November 21, 2014 “@GantosJ: the $SPY reaching New All Time High 207.27 in the PM ... the Bulls are in full control !!!!” Remember 400K+ 215 Dec call trades?
— Amit Gupta (@amitp_gupta) November 21, 2014 $CYTX rock bottom of chart, recent insider buying, multiple catalysts on the horizon. Prime Jan effect candidate.
— BiotechBreakthroughs (@BioBreakthrough) November 21, 2014 $ZGNX I think people are confused, only seeing Purdue's approval as a competition. But it's more of win-win situation.
— DigitalDeath (@itchibahn) November 21, 2014 $MDVN $100 higher than where I initiated on it back in 2011 while at BSR. Seems like forever ago.
— David Miller (@AlpineBV_Miller) November 21, 2014 All time top:)
— Festo (@Festo50) November 21, 2014 
RSS Feed
